Home > Revlimid > Embolic stroke > Revlimid and Embolic stroke
Review: could Revlimid cause Embolic stroke?
We study 42,901 people who have side effects while taking Revlimid from FDA and social media. Among them, 9 have Embolic stroke. Find out below who they are, when they have Embolic stroke and more.
Get connected: join a mobile support group for people who take Revlimid and have Embolic stroke >>>
Revlimid (latest outcomes from 42,992 users) has active ingredients of lenalidomide. It is often used in multiple myeloma.
Embolic stroke (stroke due to obstruction due to an embolus) (latest reports from 6,889 patients) has been reported by people with high blood pressure, birth control, stroke, high blood cholesterol, pain.
On Oct, 28, 2014: 42,901 people reported to have side effects when taking Revlimid. Among them, 9 people (0.02%) have Embolic Stroke.
Time on Revlimid when people have Embolic stroke * :
|< 1 month||1 - 6 months||6 - 12 months||1 - 2 years||2 - 5 years||5 - 10 years||10+ years |
|Embolic stroke||40.00%||40.00%||0.00%||0.00%||20.00%||0.00%||0.00% |
Gender of people who have Embolic stroke when taking Revlimid * :
|Embolic stroke||61.54%||38.46% |
Age of people who have Embolic stroke when taking Revlimid * :
|Embolic stroke||0.00%||0.00%||0.00%||0.00%||0.00%||0.00%||30.77%||69.23% |
Severity of Embolic stroke when taking Revlimid ** :
How people recovered from Embolic stroke ** :
Top conditions involved for these people * :
- Myelodysplastic syndrome (7 people, 77.78%)
- Multiple myeloma (6 people, 66.67%)
- Pain (4 people, 44.44%)
- Blood pressure increased (1 people, 11.11%)
Top co-used drugs for these people * :
- Insulin (4 people, 44.44%)
- Oxycontin (4 people, 44.44%)
- Dilaudid (4 people, 44.44%)
- Tarceva (4 people, 44.44%)
- Oxycodone hcl (4 people, 44.44%)
* Approximation only. Some reports may have incomplete information.
** Reports from social media are used.
How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.
Do you have Embolic Stroke while taking Revlimid?
Get connected! Join a mobile support group:
- support group for people who take Revlimid and have Embolic Stroke
- support group for people who take Revlimid
- support group for people who have Embolic Stroke
Can you answer these questions (what is this?):
More questions for: Revlimid, Embolic stroke
More reviews for: Revlimid, Embolic stroke
On eHealthMe, Revlimid (lenalidomide) is often used for multiple myeloma. Find out below the conditions Revlimid is used for, how effective it is, and any alternative drugs that you can use to treat those same conditions.
What is Revlimid used for and how effective is it:
Other drugs that are used to treat the same conditions:
Could it be a symptom from a condition:
Drugs in real world that are associated with:
Could your condition cause it?
Related drug studies for: Revlimid, Embolic stroke
Recent Revlimid related drug comparison:
More related comparison studies for: Revlimid, Embolic stroke
NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.